Core Insights - Daxor Corporation is participating as an exhibitor at the American College of Cardiology Annual Scientific Session, showcasing its innovative Blood Volume Analyzer [1][2] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, addressing the critical issue of accurately measuring blood volume to improve patient care and reduce healthcare costs [5] - The company has developed a rapid, portable Blood Volume Analyzer (BVA) that is FDA-cleared and provides over 95% accuracy in quantifying total blood, plasma, and red cell volume [2][5] Product Benefits - The BVA system replaces subjective clinical guesswork with objective data, which is essential for optimizing fluid management and discharge timing in patients [3] - Peer-reviewed studies indicate that BVA-guided care can lead to a 56% reduction in 30-day readmissions and an 82% reduction in 30-day mortality, demonstrating significant value for healthcare providers [3] Market Context - The BVA addresses the $3.5 billion annual Medicare burden associated with heart failure readmissions in the United States, highlighting its potential impact on healthcare costs [2] - Daxor's technology is positioned for scalability across both inpatient and outpatient care environments, enhancing its market reach [3]

Company Overview - Daxor Corporation is a NASDAQ-listed company focused on advancing optimal fluid management through blood volume analysis across the healthcare system [2][3] - The company is headquartered in Oak Ridge, Tennessee, and operates a 20,000 square foot state-of-the-art facility for research, development, and production [3] Product Information - Daxor produces a diagnostic drug called Volumex, which is a radiopharmaceutical diagnostic used for blood volume analysis [4] - The company has the capacity to produce up to 200,000 test kits per year for its diagnostic test [3]

Daxor Corporation Conference Call Summary Company Overview - **Company Name**: Daxor Corporation - **Ticker**: DXR - **Headquarters**: Oak Ridge, Tennessee - **Industry**: Pharmaceutical Diagnostics, specifically Radiopharmaceuticals - **Core Product**: Volumex, a diagnostic drug for blood volume analysis - **Business Model**: Razor-and-blades model, generating recurring revenue through test kit sales [2][3][4] Core Points and Arguments - **Mission**: To enable optimal fluid management through blood volume analysis across the healthcare system [2] - **Market Size**: Approximately 134 million patients in the U.S. have conditions where blood volume management is critical, including 7 million heart failure patients [6][27] - **Clinical Importance**: Blood volume management is essential in various medical conditions such as heart failure, critical care, sepsis, and surgical blood loss [5][6] - **Uncertainty in Current Practices**: Current methods for assessing blood volume are indirect and often lead to suboptimal care due to reliance on proxy measures [10][11] - **Unique Offering**: Daxor is the only company with an FDA-approved direct measurement test for blood volume, providing accurate diagnostics that improve patient outcomes [12] Key Data and Results - **Test Utilization**: Over 75,000 tests shipped to more than 100 medical centers, with 170 peer-reviewed studies validating its accuracy [13] - **Impact on Patient Outcomes**: A study showed a 56% reduction in 30-day readmissions, 82% reduction in 30-day mortality, and 86% reduction in 1-year mortality for patients receiving blood volume analysis [21][22][23] - **Cost-Effectiveness**: The test is considered inexpensive relative to the complex problems it addresses, leading to better patient care and reduced healthcare costs [25][26] Recent Developments - **New Analyzer**: FDA clearance received for a new rapid portable analyzer, enhancing test processing speed and deployment [16][17] - **Sales Growth**: Operating revenue increased by 45% year-over-year for 2025, with a price increase for the diagnostic test implemented [29][30] - **Funding and Partnerships**: Secured over $5.6 million in Department of Defense contracts and $1.1 million in NIH grants [30] - **Production Strategy**: Plans to integrate key suppliers to bring 100% of production in-house by the end of the year [31] Market Expansion Strategy - **Target Markets**: Beyond heart failure, the test is applicable to critical care, nephrology, oncology, and outpatient settings [27] - **Projected Market Size**: Potential $70 billion market for heart failure alone, assuming a $1,000 test price and 30% market penetration [28] - **Sales Team Expansion**: Currently ramping up the sales team to accelerate market penetration [29] Financial Overview - **Market Capitalization**: Approximately $66 million with 5.83 million shares outstanding [34] - **Clean Capital Structure**: No debt or warrants, with a high insider ownership of 48.3% [34][35] - **Cash Flow**: Achieved cash flow breakeven on a cash-on-cash basis, with a cash burn of only $289,000 for the year [37] Leadership Team - **Key Personnel**: Led by experienced professionals including Chief Medical Officer Dr. John L. Jefferies and Chief Scientific Officer Jonathan Feldschuh [37][38] Conclusion Daxor Corporation is positioned to significantly impact the healthcare industry through its innovative blood volume analysis technology, with strong clinical evidence supporting its efficacy and a clear strategy for market expansion and revenue growth.

Advancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will showcase its new, portable blood volume analyzer at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress (Booth #906) at McCormick Place in Chicago, IL, from March 22–24. The new device delivers rapid, lab-quality results making B ...

Core Insights - Daxor Corporation will participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026, with CEO Michael Feldschuh presenting on March 10 at 2:00 PM ET [1] - The company focuses on addressing the critical issue of accurately measuring blood volume, which is essential for improving patient care and reducing hospital stays for conditions like heart failure [2] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, offering a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic system that provides real-time, precise data [2] - The company has 50 years of experience and operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S., positioning it for market expansion [2] - Daxor's technology aims to enhance individualized treatment decisions, thereby improving patient outcomes and increasing efficiencies in value-based healthcare [2]

Core Insights - Daxor Corporation experienced a transformative year in 2025, marked by significant growth in its operating division and a substantial increase in total net assets [1][6] FDA Milestone & Commercial Momentum - The company received FDA 510(k) clearance in August 2025 for its next-generation Blood Volume Analyzer, which is three times faster than previous models and developed under contract with the U.S. Department of Defense [2] - Daxor is utilizing newly raised capital to assemble these units and expand its commercial sales team in response to positive market feedback [2] Financial Performance Highlights - Total net assets reached $45,887,266 as of December 31, 2025, an increase of over $10 million from the previous year [7] - Net Asset Value per share increased to $9.07, representing a gain of $1.82 per share compared to December 31, 2024 [7] - The company recorded net realized gains on investment activity of $745,334 for the fiscal year [7] - Unaudited operating revenues increased by 45% year-over-year, driven by sales of diagnostic kits and military contracts [7] - The operating division improved its loss to $268,598 from a loss of $1,614,545 in 2024, despite heavy investments in R&D and sales team expansion [7] Operating Division Momentum - Daxor's operating division saw remarkable expansion due to increased market adoption of its Blood Volume Analysis (BVA) technology [4] - The company successfully closed a $9 million registered direct offering in January 2026, significantly strengthening its working capital for accelerated commercialization [4] - Daxor plans to transition its regulatory reporting framework to the Securities Exchange Act of 1934 to simplify financial disclosures and provide standardized GAAP metrics [5] Company Overview - Daxor Corporation addresses the critical issue of accurately measuring blood volume, which is essential for optimal care in high-cost medical conditions [6] - The company operates a state-of-the-art manufacturing facility and is ISO certified, positioning it for accelerated market expansion [8]

Core Insights - Daxor Corporation is expanding into the outpatient cardiology market by opening a new BVA program in Southern Middle Tennessee, enhancing chronic disease management through advanced blood volume measurement technology [1][3] - The ezBVA Lab workflow will provide a 24-hour turnaround for blood volume metrics, facilitating rapid clinical decisions for cardiology patients [2] - Daxor's technology boasts 98% accuracy, allowing clinicians to make data-driven fluid management decisions without capital investment, which can improve patient outcomes and reduce healthcare costs [3] Company Overview - Daxor Corporation addresses the critical issue of accurately measuring blood volume, which is essential for optimal patient care and reducing hospital stays and readmissions for conditions like heart failure [4] - With 50 years of experience, Daxor manufactures and distributes its FDA-cleared Blood Volume Analysis diagnostic, providing real-time, precise data to support individualized treatment decisions [4] - The company operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S., positioning itself for accelerated market expansion [4]

Core Insights - Daxor Corporation intends to transition its primary regulatory reporting framework from the Investment Company Act of 1940 to the Securities Exchange Act of 1934, reflecting the company's growth and strategic maturation in its core diagnostic technology business [1][4] Company Focus - The principal focus of Daxor remains on the development and commercialization of its Blood Volume Analysis (BVA) technology, which is the only FDA-cleared diagnostic blood test that provides objective, patient-specific quantification of total blood volume status and composition [2] Key Highlights of the Transition - The transition back to Exchange Act reporting is seen as a financial validation of Daxor's growth strategy, aligning regulatory and operational frameworks with its identity as a high-growth medical diagnostic company [4] - The company anticipates completing the necessary regulatory steps to effectuate the change in reporting status by the end of the second quarter, pending required regulatory filings and approvals [4] Operational and Financial Alignment - The transition validates the success of management's strategy to prioritize and rapidly grow the BVA technology division, marked by revenue increases and new customer acquisitions [8] - The company's financial profile is now more accurately represented under the Exchange Act framework, aligning its regulatory status with its identity as an innovative medical device and diagnostic technology firm [8] Enhanced Investor Clarity - Reporting under the Exchange Act will simplify financial disclosures, providing standardized GAAP metrics and benchmarks comparable to other publicly traded medical diagnostic companies, which is expected to improve transparency and attract deeper institutional interest [8]

Core Viewpoint - Daxor Corporation has entered into a definitive agreement for the purchase and sale of 765,958 shares of its common stock at a price of $11.75 per share, with expected gross proceeds of approximately $9 million [1][2]. Group 1: Offering Details - The offering is expected to close on or about January 26, 2026, subject to customary closing conditions [1]. - Lake Street Capital Markets, LLC is acting as the exclusive placement agent for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including working capital [2]. Group 3: Company Overview - Daxor Corporation addresses a significant issue in healthcare related to the inability to accurately measure blood volume, which can lead to suboptimal patient care and increased hospital stays [5]. - The company manufactures and distributes a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic system that provides real-time, precise data to improve patient outcomes [5]. - Daxor operates a state-of-the-art manufacturing facility in the U.S. and is positioned for accelerated market expansion [5].

Core Insights - Daxor Corporation is expanding its Blood Volume Analysis (BVA) platform into three new facilities, indicating accelerating market adoption and its role in precision fluid management [1][2] - The company's dual-solution strategy, which includes the on-site BVA analyzer and the CLIA-certified ezBVA Lab Service, is driving strong sales momentum as clinicians increasingly adopt this diagnostic tool [2][3] Company Overview - Daxor Corporation addresses the healthcare challenge of accurately measuring blood volume, which can lead to suboptimal care and increased costs for conditions like heart failure [3] - With 50 years of experience, Daxor manufactures and distributes its FDA-cleared BVA diagnostic, providing real-time, precise data to empower clinicians in making individualized treatment decisions [3] Recent Developments - The ezBVA Lab has been adopted by various healthcare facilities, including the Upper Midwest Integrated Health System for cardiology diagnostics and an Ohio Academic Medical Center for heart failure management [6] - The Southwest Cardiology Group Practice has onboarded the new BVA Analyzer for immediate in-office volume assessment, showcasing the tool's versatility across different healthcare settings [6]